Navigation Links
Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
Date:9/8/2010

SAN FRANCISCO and ILLKIRCH, France, Sept. 8 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene (NYSE Euronext Paris: FR0005175080), a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that they have entered into an exclusive partnership to develop and commercialize JX-594 for the treatment of solid tumors in Europe, the Commonwealth of Independent States (CIS) and the Middle East.  

JX-594, Jennerex's lead cancer biotherapeutic product, has shown anticancer activity and a well-tolerated safety profile in Phase 1 and Phase 2 clinical trials to date(1). Objective tumor response has been demonstrated in a variety of cancers including liver, colon, kidney, lung and melanoma.

Jennerex has awarded Transgene exclusive rights to develop and commercialize JX-594 in Europe, the CIS and the Middle East.  Jennerex and Transgene will co-develop JX-594 worldwide, with Transgene responsible for development costs and for clinical development in its licensed territories, pursuant to the JX-594 global development plan. Transgene is responsible for commercialization and has the right to manufacture JX-594 in the Transgene territory. As part of this agreement Transgene has made an upfront equity investment in Jennerex. Jennerex is further eligible to earn a total of up to $116 million in development and registration milestones as well as double digit royalties on a tiered structure. In addition, Jennerex has an option for co-promotion and profit-sharing in the five major European countries.

The development plan will focus initially on Hepatocellular Carcinoma (HCC), both in first line and in second line, and on colorectal cancer. Transgene and Jennerex intend to initiate a large randomized controlled phase 2b/3 clinical program in HCC patients. 
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
2. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
3. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
4. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
5. Jennerex Closes $5 Million First Tranche of Series C Financing
6. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
7. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
8. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
9. Sigma® Life Science Enters Genetically Modified Cell Market
10. Generic Drug Sector Gets Better Information on API Manufacturing Costs from Thomson Reuters and Rondaxe Enterprises
11. Bioheart Reports Significant Improvements in Heart Failure Patients from Center of Excellence Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Continuing its award-winning streak, Nerium International, ... MarCom Awards for outstanding creative achievement by its marketing ... Award, the organization’s top honor, in the Branding category ... in April of this year. The event showcased top ... Nerium was awarded a Gold MarCom Award in the ...
(Date:11/26/2014)... SoundConnect , an award winning ... announce that Darren Suders has joined the team as ... drive the partner program through innovative offerings, ... , Darren brings more than 10-years of channel telecommunication ... channel operations, from policy development, to partner education and ...
(Date:11/26/2014)... MINNEAPOLIS , Nov. 25, 2014 Bio-Techne ... it has appointed Robert Gavin to serve ... of the Protein Platforms Division.  Mr. Gavin will be ... business segment, which includes the ProteinSimple business acquired in ... San Jose, California -based ProteinSimple ...
(Date:11/24/2014)... DUBAI , UAE, November 24, 2014 ... prestigious "Sheikh Hamdan Bin Rashid Al Maktoum Awards for ... in Dubai, United Arab Emirates , ... http://photos.prnewswire.com/prnh/20141124/717861 ) , The Carter Center ... Medical Services is actively involved in numerous programs that ...
Breaking Biology Technology:Nerium International™ Wins One Platinum, Two Gold MarCom Awards 2SoundConnect Appoints Director of Channel Development & Sales 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3Five US Winners Among Recipients of Hamdan Medical Awards 2
... Mass., Dec. 21 LeMaitre Vascular,Inc. (Nasdaq: ... and,implants, yesterday acquired Biomateriali S.r.l., a privately held ... cash, the assumption,of euro 0.8 million in intercompany ... 1.5 million. The acquisition was structured as a ...
... Dec. 20 MacAndrews & Forbes Holdings Inc.,announced ... President for Life,Sciences, who also serves as Chief ... to the National Biodefense Science Board (NBSB). The,NBSB ... Secretary Mike Leavitt,on scientific, technical and other matters ...
... the Record and Provide Accurate Information to ... ... VaxGen,Inc. (Pink Sheets: VXGN), (Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO ), ... announced on,November 12, 2007 that their respective Boards of Directors had ...
Cached Biology Technology:LeMaitre Vascular Acquires Biomateriali, a Vascular Graft Manufacturer 2LeMaitre Vascular Acquires Biomateriali, a Vascular Graft Manufacturer 3Department of Health & Human Services Names Dr. Eric Rose to National Biodefense Science Board 2VaxGen Addresses MPM Claims in Letter to Stockholders 2VaxGen Addresses MPM Claims in Letter to Stockholders 3VaxGen Addresses MPM Claims in Letter to Stockholders 4VaxGen Addresses MPM Claims in Letter to Stockholders 5VaxGen Addresses MPM Claims in Letter to Stockholders 6VaxGen Addresses MPM Claims in Letter to Stockholders 7VaxGen Addresses MPM Claims in Letter to Stockholders 8VaxGen Addresses MPM Claims in Letter to Stockholders 9
(Date:11/6/2014)... metastasis, yet progress in preventing and treating migratory ... particularly challenging to design drugs that work against ... biology at Harvard Medical School. , "Unfortunately, ... metastasized." , Gujral and colleagues have now identified ... understand how metastasis begins. Their findings may also ...
(Date:11/6/2014)... Insilico Medicine, Inc, a Baltimore-based bioinformatics company focused ... announced a research collaboration with the international leader ... (OTC: CSBR). , "There are many companies utilizing ... Oncology,s TumorGraft technology is unique in a way ... generating vast amounts of valuable data. Our bioinformatic ...
(Date:11/5/2014)... – Kelly Redmond has dedicated his career to ... to a general audience. , As deputy director ... Center at Nevada,s Desert Research Institute, Redmond has ... management, application and dissemination of climate data to ... Fall Meeting in San Francisco on December 15-19, ...
Breaking Biology News(10 mins):Migration negation 2Migration negation 3Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2
... the world from dying off, deep cuts in carbon ... Carnegie,s Katharine Ricke and Ken Caldeira. They find that ... ocean chemistry conditions by the end of the century ... work will be published July 3 by Environmental ...
... A single systemic dose of special immune cells prevented ... model of kidney transplantation, according to experts at the ... available in the online version of the American ... eventual human trials of the technique. , Organ transplantation ...
... 4000 elk of the Clarks Fork herd leave crowded ... into the highlands of the Absaroka Mountains, where they ... snowmelt. It,s a short trip (40-60 kilometers) by migratory ... fences, metropolitan areas, and other human-built barriers. But it ...
Cached Biology News:Major changes needed for coral reef survival 2Dendritic cell therapy improves kidney transplant survival, Pitt team says 2Declining fortunes of Yellowstone's migratory elk 2Declining fortunes of Yellowstone's migratory elk 3Declining fortunes of Yellowstone's migratory elk 4
... Stainless Steel Staining tray 19 x 29 ... staining and blot processing.Automated staining of Coomassie ... nucleic acid analysis. Prepares blots for high ... control of protocol, solution, volume, and processing ...
Complement C1r [Human]...
Cytidine 5'-Triphosphate, Sodium (CTP), 1 g. Category: Nucleotides & Enzymes & Biochemicals, Nucleotides, Additional Nucleotide Products....
... designs oligos for SYBR Green, TaqMan, LNA ... FRET assays. Highly specific primers are designed ... interpreting BLAST search results. Primer efficiency is ... by connecting to the Mfold server. Beacon ...
Biology Products: